Frontiers in Clinical Drug Research - CNS and Neurological Disorders

Volume: 1

Indexed in: EBSCO, Scopus.

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



A Novel Pharmacological Approach for the Treatment of Posttraumatic Stress Disorder Using Cognitive Enhancers

Pp. 116-134 (19)

Shigeto Yamamoto and Shigeru Morinobu

Abstract

Posttraumatic stress disorder (PTSD) is a complex disorder associated with an intricate biological and psychological symptom profile and various common comorbidities. Despite the availability of various treatment strategies, PTSD is often difficult to treat. Several researchers have proposed that impaired fear extinction is involved in the pathophysiology of PTSD. Therefore, enhancing fear extinction using cognitive enhancers could be a new modality for the treatment of PTSD. To date, various cognitive enhancers that alter GABAergic, glutamatergic, dopaminergic, noradrenergic, and cannnabinoid pathways have been investigated in animal models of fear extinction. The present review focuses on D-cycloserine (DCS), a partial agonist of N-methyl-D-aspartate (NMDA) receptors, and on histone deacetylase (HDAC) inhibitors. Herein, we provide an overview of the effects of these agents, the clinical implications and drawbacks associated with their use, and directions for future research. Many preclinical and clinical studies of DCS have demonstrated a facilitating effect on fear extinction. Thus, among various cognitive enhancers, DCS seems to be the most promising agent for the treatment of PTSD. However, recent clinical studies of DCS in PTSD have not demonstrated sufficient efficacy. Several preclinical studies have also revealed that administration of HDAC inhibitors with exposure therapy can enhance fear extinction. However, no clinical studies have been conducted to assess the efficacy of HDAC inhibitors in PTSD; therefore, it is recommended that clinical trials of HDAC inhibitors be conducted in the future.

Keywords:

Cognitive enhancers, D-cycloserine, fear extinction, histone, HDAC inhibitors, posttraumatic stress disorder, vorinostat, NMDA receptor, NR2B, hippocampus.

Affiliation:

Department of Psychiatry and Neurosciences, Applied Life Sciences Institute of Biomedical & Health Sciences, Hiroshima University 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan.